ES2112271T3 - Uso del factor-4 de plaqueta (pf4) o fragmentos del mismo en la fabricacion de medicamentos para la neutralizacion de la heparina. - Google Patents

Uso del factor-4 de plaqueta (pf4) o fragmentos del mismo en la fabricacion de medicamentos para la neutralizacion de la heparina.

Info

Publication number
ES2112271T3
ES2112271T3 ES91905244T ES91905244T ES2112271T3 ES 2112271 T3 ES2112271 T3 ES 2112271T3 ES 91905244 T ES91905244 T ES 91905244T ES 91905244 T ES91905244 T ES 91905244T ES 2112271 T3 ES2112271 T3 ES 2112271T3
Authority
ES
Spain
Prior art keywords
heparin
medicines
neutralization
fragments
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91905244T
Other languages
English (en)
Inventor
Jacquelynn J Cook
Stefan Niewarowski
Theodore E Maione
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Original Assignee
Repligen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corp filed Critical Repligen Corp
Application granted granted Critical
Publication of ES2112271T3 publication Critical patent/ES2112271T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA CIRCULACION DE HEPARINA EN UN MAMIFERO PUEDE NEUTRALIZARSE SIN DEPLECION SUSTANCIAL DE PLAQUETAS O LEUCOCITOS MEDIANTE LA ADMINISTRACION AL MAMIFERO DE UNA CANTIDAD DE NEUTRALIZACION DE HEPARINA DE PF4 O RPF4 PURIFICADA O UN FRAGMENTO DE NEUTRALIZACION DE HEPARINA DEL MISMO.
ES91905244T 1990-02-16 1991-02-14 Uso del factor-4 de plaqueta (pf4) o fragmentos del mismo en la fabricacion de medicamentos para la neutralizacion de la heparina. Expired - Lifetime ES2112271T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48087390A 1990-02-16 1990-02-16

Publications (1)

Publication Number Publication Date
ES2112271T3 true ES2112271T3 (es) 1998-04-01

Family

ID=23909691

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91905244T Expired - Lifetime ES2112271T3 (es) 1990-02-16 1991-02-14 Uso del factor-4 de plaqueta (pf4) o fragmentos del mismo en la fabricacion de medicamentos para la neutralizacion de la heparina.

Country Status (9)

Country Link
EP (1) EP0515550B1 (es)
JP (1) JPH05505602A (es)
AT (1) ATE161183T1 (es)
CA (1) CA2075957A1 (es)
DE (1) DE69128465T2 (es)
DK (1) DK0515550T3 (es)
ES (1) ES2112271T3 (es)
GR (1) GR3025878T3 (es)
WO (1) WO1991012017A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585095A (en) * 1993-09-14 1996-12-17 Regents Of The University Of Minnesota Method to enhance thrombomodulin APC generation using cationic proteins
AU6670198A (en) * 1997-02-28 1998-09-18 The Texas A & M University System Heparan sulfate/heparin interacting protein compositions and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844895A (en) * 1985-11-01 1989-07-04 New York University Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses

Also Published As

Publication number Publication date
DE69128465D1 (de) 1998-01-29
GR3025878T3 (en) 1998-04-30
WO1991012017A1 (en) 1991-08-22
EP0515550A1 (en) 1992-12-02
DE69128465T2 (de) 1998-04-16
JPH05505602A (ja) 1993-08-19
EP0515550B1 (en) 1997-12-17
CA2075957A1 (en) 1991-08-17
DK0515550T3 (da) 1998-02-02
EP0515550A4 (en) 1993-06-30
ATE161183T1 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
ES2062355T3 (es) Composicion farmaceutica que comprende loratadina, ibuprofeno y pseudoefedrina.
ES2080837T3 (es) Tratamiento de estados y enfermedades.
IT1169776B (it) Preparato di medicamento per migliorare i sintomi del cancro
PT100199A (pt) Combinacao antiviral de nucleosidos e processo para a sua preparacao
ES535702A0 (es) Dispositivo para astillar material del tipo de la madera
IT1174649B (it) Trattamento del riassorbimento di osso alveolare
ES2061307T3 (es) Empleo del principio activo azelastina y eteres de glicerol para combatir enfermedades psoriasicas.
IT9067939A0 (it) orientamento del fascio
ES2037808T3 (es) Procedimiento para la obtencion de medicamentos para la profilaxis y terapia de enfermedades producidas por retrovirus.
PT100914A (pt) Uso de compostos capazes de sofrer uma permuta mista com dissulfureto, com uma ligacao dissulfureto, no tratamento de infeccao por hiv
ES2128348T3 (es) Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
ES2112271T3 (es) Uso del factor-4 de plaqueta (pf4) o fragmentos del mismo en la fabricacion de medicamentos para la neutralizacion de la heparina.
ES2055314T3 (es) Tratamiento de disfuncion leucocitaria con gm-csf.
BR8403616A (pt) Artigo esterilizado e estabilizador por radiacao e processo para sua preparacao,artigo flexivel,processo para esterilizar e estabilizar por radiacao uma poliolefina
PT88067A (pt) Processo para a purificacao de proteina tecidual pp4 placentaria
BR6805159D0 (pt) Fibra de alto peso molecular composicao em que a mesma e utilizada e processo de tratamento de fibra
BR9007070A (pt) Vacina para o tratamento preventivo de infeccao por vermes trematoides do figado em ruminantes
IT1168778B (it) Impiego di derivati dello zucchero per la profilassi e terapia di infezioni da virus e preparati farmaceutici che contengono tali composti
ES519701A0 (es) Procedimiento para la preparacion de derivados de pantenol.
IT1163107B (it) Composizioni farmaceutiche e loro uso nel trattamento del glaucoma
BR8102386A (pt) Aperfeicoamento em processo de cura de borracha insaturada
SE8802193D0 (sv) Externally applicable, antiviral pharmaceutical composition accumulating in the skin and process for the preparation of the same
ES2061718T3 (es) Utilizacion de antigestagenos para la preparacion de medicamentos.
BR9106596A (pt) Processo para o tratamento ou profilaxia de uma infeccao associada com retrovirus,uso,composicao farmaceutica para o tratamento ou profilaxia de uma infeccao associada com retrovirus,e,composto
IT9086214A1 (it) Cura o guarigione del cancro o maurosalute

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 515550

Country of ref document: ES